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We can now cure over 70% of all childhood cancers, and this cure rate approaches 
90% for some tumours1. Enhanced supportive care for dose-intense treatment 
regimens imposed on a cancer incidence stable over the last 40 years2 are 
responsible for this success. Where survival is so high, however, further attempts to 
increase it must be balanced against the multi-organ toxicities to the majority of 
developing children. Though not necessarily impotent, 15-30% of male survivors are 
rendered infertile3, either from hypothalamopituitary-gonadal exposure to 
chemoradiation4 or from diseases such as Hodgkin’s lymphoma5.  
 
In today’s society, 1 in 6 healthy couples seek help from reproductive clinics to 
conceive6 with rapid advancements in assisted reproductive technology (ART) being 
made in the last 2 decades. This includes cryopreservation of gametes and embryos 
prior to gonadotoxic cancer therapies to preserve fertility in adults. This article 
explores the possibilities and particular developmental and ethical issues 
surrounding sperm cryopreservation in young boys with cancer, and examines the 
unique legal implications of fertility counselling in adolescence. 
 
The impact of childhood cancer treatment on male fertility 
Spermatogenesis begins only at puberty. This process requires meiotic division of 
diploid spermatogonia to produce haploid spermatozoa, a process which continues 
thereafter throughout adult life. Spermatogenesis requires sufficient intratesticular 
testosterone production maintained by pituitary-derived follicular-stimulating 
hormone (FSH) and luteinising hormone (LH) with negative gonadal feedback from 
inhibin B (Sertoli cells) and testosterone (Leydig cells). Both disease- and treatment-
related factors can damage the hypothalamopituitary-testicular axis at one or 
multiple levels (Figure 1), thereby compromising male reproductive capacity.  
 
Chemotherapy 
The rapidly dividing sperm-producing testicular seminiferous epithelium is highly 
susceptible to cytotoxic damage, its extent determined by drug type, cumulative 
drug dosage and patient age at exposure. By contrast, the testosterone-producing 
Leydig cells are relatively robust. Consequently, pubertal sexual development may 
proceed normally (and sometimes early), the only sign of gonadotoxicity and future 




Because cancer treatment protocols are multidrug regimens, the individual effect of 
specific drug types has proved difficult to accurately determine. However, most 
alkylating agents (e.g. cyclophosphamide, busulfan, melphalan) and nitrosureas (e.g. 
lomustine) demonstrate dose-dependent gonadotoxicity; the UK Children’s Cancer 
and Leukaemia Group (CCLG) and British Fertility Society (BFS) have provided helpful 
“guesstimates” of the ‘gonadotoxicity risk’ of current common children’s cancer 
treatment regimens (Table 1)4,7 in three broad categories – low (<20%), medium (20-
80%) and high (>80%). Alkylating agents (e.g. cyclophosphamide) are most likely to 
cause future subfertility, whilst protocols for acute lymphoblastic leukaemia (ALL) 
(vincristine, methotrexate, cytarabine) are least likely to do so. 
 
Radiotherapy 
Radiotherapy may affect fertility at more than one level on the 
hypothalamopituitary-testicular axis (Figure 1). Firstly, the testis is vulnerable to 
increasing doses of irradiation which differentially affect the seminiferous epithelium 
and Leydig cells (Table 2)8,9. In adults, fractionated doses as low as 0.1 Gy may cause 
temporary azoospermia whilst doses of 2-3 Gy are likely to prevent spermatic 
recovery long-term. Larger doses of 10-12 Gy as used in total body irradiation 
damage both Leydig and Sertoli cell function and, if given concurrently with 
chemotherapy, have additive effects. LH hypersecretion can partially compensate for 
mild Leydig cell dysfunction with near-normal testosterone values (subclinical 
hypergonadotrophic hypogonadism), but the long-term impact on bone strength and 
cardiac health is unknown. 
 
Cranial irradiation, used in high dose (>40 Gy) and primarily for centrally positioned 
brain tumours, may reduce hypothalamopituitary function and result in 
hypogonadotrophic hypogonadism10. In the developing child this manifests as 
pubertal delay or arrest, although in the context of pre-existing pituitary disease or 
tumour these are the more likely causative factors. By contrast, early or precocious 
puberty is a typical manifestation of any cranial injury to the young brain (including 
disease, surgery or irradiation) but its evolution does not preclude later pubertal 
arrest and eventual gonadotrophin deficiency affecting both LH-testosterone and 
FSH-spermatogenic pathways and causing impotence and subfertility respectively. 
Only the former can be treated with testosterone replacement therapy. 
 
Disease 
Occasionally, the disease itself can cause testicular dysfunction. Hodgkin’s disease 
has been associated with pre-treatment abnormalities in semen quality even in the 
absence of testicular infiltration5. The pathogenesis of this phenomenon is poorly 
understood but is thought to relate to disease-induced inflammatory processes. 
 
Current fertility preservation strategies 
In mature adults, pre-treatment sperm cryopreservation has been the most 
successful method of fertility preservation since the 1950s. Spermatozoa are 
remarkably resistant to storage and freeze-thawing processes, and healthy offspring 
without congenital anomalies have been reported from sperm stored for up to 28 
years11. Separately stored “straws” of spermatozoa can be thawed as required and 
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used in fertility treatments either directly by intrauterine insemination (IUI) or by 
intracytoplasmic sperm injection (ICSI), a technique available since 1992 which has 
markedly reduced the number of viable spermatozoa required to single numbers12. 
 
Requesting and obtaining masturbatory semen samples from older post-pubertal 
males is relatively straightforward. However, even ill adults may fail to produce a 
specimen in this way. For these patients and younger boys unable to produce a 
sample due to psychological or sexual immaturity, religious or cultural beliefs, 
alternatives such as rectal electrostimulation, penile vibratory stimulation, surgical 
extraction (TESE) under general anaesthesia, and even experimental techniques such 
as testicular tissue storage have been considered but not widely practised. 
 
To facilitate service delivery, what remains unclear is exactly when during pubertal 
maturation boys are able to spontaneously ejaculate semen containing viable sperm. 
Spermaturia – the appearance of sperm in the urine by retrograde ejaculation – has 
been documented in healthy boys as young as 11.7 years of age and at a minimum 
testicular volume of 4.7 ml with little or no pubic hair development (Tanner stage P1, 
G2) and before peak height velocity13. The age range for initial spermaturia however 
is wide and up to 17.5 years. Although it has been used as an estimate of true 
spermarche there is no documentation of what triggers spermatogenesis, its 
correlation with pubertal staging and the ability to voluntarily donate semen, whilst 
spermatozoa obtained from urine are less viable and hence unsuitable for 
cryopreservation. 
 
Our own pioneering service for adolescent boys at University College London 
Hospital since 1999 
 
Over 10 years ago, with the support of colleagues in child psychiatry, reproductive 
health and haematology/ oncology contributing to the development of age-
appropriate information leaflets, awareness campaigns and streamlined risk-
assessments and referrals, we set up a pioneering endocrine/ fertility assessment 
and counselling service for adolescents. This was targeted at males with cancer aged 
12 to 18 years referred to our tertiary centre for high dose therapies.  
 
The repeated 3-4 yearly audit cycles of service in a total of 222 boys over that time 
have demonstrated a surprisingly consistent and unchanging counselling rate of 
some 70% but with an appropriately greater prioritisation of those at highest 
‘gonadotoxicity risk’ over time. However, the relative paucity (30.0%) of documented 
pubertal clinical examinations despite good biochemical marker measurements 
(70.3%) and high (68.4%) patient acceptability of the counselling process persists to 
date. 34.2% of the total cohort (and 65.0% of those actually attempting storage) 
banked viable sperm produced by masturbation, the youngest boys being 12.6 years 
at Tanner stage 3+ and/ or with a testicular volume of ≥8 mls14. Importantly, it was 
hormone parameters of virilisation (testicular volume, plasma LH and testosterone 
concentrations), not age per se, which correlated with successful storage, whilst 
parameters of spermatogenesis (plasma FSH concentration) determined the 
normality of sperm concentrations. The role of age came into play only as a 
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There are currently no proven fertility preservation techniques for prepubertal boys 
(testicular volume <4 mls). Cryopreservation of diploid spermatogonial cells obtained 
by testicular biopsy for later post-cure auto-transplantation or in vitro maturation to 
spermatozoa (as currently debated in young women) is still experimental without 
successful conceptions, even in animal models. Auto-transplantation carries a 
theoretical risk of reintroducing malignant cells, particularly in haematological 
malignancies where the testes are potential sites of metastases. Other prophylactic 
techniques such as testicular shielding during radiotherapy or the administration of 
GnRH analogues or testosterone to render cell division quiescent and less 
susceptible to cytotoxins have limited, if any, practical success. 
 
Legal, ethical and practical considerations 
The storage and use of haploid gametes and embryos is governed by the Human 
Fertilisation and Embryology (HFE) Act15 – this mandates personal, not proxy, 
informed consent in line with reproductive rights. Thus, unlike other paediatric 
procedures – for instance consenting for an appendicectomy – parents cannot give 
valid consent on a teenager’s behalf; any minor (under 18 or 16 years of age 
respectively in England and Scotland) must be judged intellectually (“Gillick”) 
competent to consent without coercion. Written consent to disclosure, HIV, 
hepatitis B and C testing and the use of stored samples after death or mental 
incapacitation is additionally required at this difficult time. Paradoxically, the legal 
loophole in which diploid pre-pubertal testicular tissue does not fall under HFE 
jurisdiction until such time as it becomes haploid leaves pre-pubertal boys 
potentially open to harm from experimentation – such as surgical removal of pre-
meiotic spermatogonia – under the Common Law of parental consent even if the 
sole intent to preserve fertility appears well intended. 
 
There are few, if any, adolescent-tailored sperm banking and counselling facilities in 
the UK, and there is debate as to how adult services might be modified to meet their 
specific needs (e.g. the environment, written information and pornographic material 
provided). The increased press focus on fertility preservation and the National 
Institute of for Health and Clinical Excellence’s (formerly NICE) recommendations 
suggests such a service might be offered more widely. However, whilst the young 
age of these increasing number of survivors would indicate a need for longer-term 
storage, historically, few stored samples have ever been used. This would suggest 
adult survivors either retain or do not ultimately want fertility, but also that patients 
at highest risk of subfertility are those most heavily treated and likely to die from 
aggressive disease or treatment-related complications.  
 
An adolescent fertility counselling service (Table 4) 
The patient perspective 
Oncologists may perceive reproduction as too sensitive and inappropriate a topic to 
broach with adolescents already undergoing a complex counselling and consent 
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process for cancer treatment16. However, the few studies in this area indicate 
surprising awareness amongst adolescents, who in fact welcome discussion and 
choice – a positive experience at this stage of their disease17. 
 
Pre-treatment fertility assessment 
The young teenager has unique ethicolegal, physical, psychosexual and intellectual 
needs very different from the fully mature adult. To be fit for purpose any 
adolescent fertility service should routinely, consistently and reliably measure and 
record pubertal staging and testicular volumes; this is but one step further than the 
routine examination of the testes required to exclude malignant involvement. Paired 
with pre-treatment plasma endocrine biochemistry (LH, FSH, testosterone ± inhibin 
B where possible), this baseline assessment should form the gold standard against 
which service adherence might be judged and audited. It is vital not only to inform 
the counselling process and the individual patient’s chances of producing a viable 
sperm sample but also to assess future serial change indicative of gonadotoxicity 
and/ or spermatic recovery with time. Since we have found that immediately prior 
(within 6 days) commencement of chemotherapy is highly likely to reduce sample 
viability by >75%14, if it is to be successful in those at high risk judged from Table 2, 
fertility preservation should be given earlier and higher priority in the cancer 
counselling process, even to the point of delaying cancer treatment to allow several 
attempts where possible. 
 
Post-treatment fertility assessment 
The long-term follow-up of teenage cancer survivors has not to date emphasised 
routine fertility assessment, semen analysis and/ or sperm banking (against a future 
relapse) in those still minors (<18 years) at the end of cancer therapy. However, 
counselling young boys and supporting them to donate interval post-treatment 
semen samples together with routine pubertal and biochemical assessment would 
provide the data needed to inform future age-appropriate services and sperm 
storage facilities based on the true gonadotoxicity (and time to recovery) of different 
cancer treatment regimens and their clinical correlates. This would concur with the 
2003 BFS consensus recommendation that where sperm was not cryopreserved 
before treatment, a further opportunity at least 3 months from the end of treatment 
(to reduce the risk of DNA damage) should be offered7. For the counselling process 
to be truly complete, it should ensure understanding of the difference between 
potency (likely to be preserved or otherwise easily replaced) and fertility; for those 
unable or choosing not to cryopreserve sperm pre-treatment, there is still well-
documented potential for recovery of natural fertility even 5 years after treatment18 
and the consequent need for contraception in all. Testicular self-examination should 




As ART continues to rapidly evolve, fertility counselling in adolescence presents a 
specific and growing challenge. Government-level debate on the future role of the 
HFEA would do well to give consideration to the needs of this cohort who are 
increasingly campaigning for protection of their reproductive rights through patient 
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groups such as the Teenage Cancer Trust. Meanwhile, clinicians can be reassured 
that the large majority of young teenagers welcome the discussion and can exercise 
appropriate informed choice even in the context of a life-threatening illness. There 
should thus be ample opportunity to discuss options available to them both before 
and after cancer treatment with concurrently improved documentation of consent 
and clinical examination to make the service truly tailored to the adolescent. 
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Low risk (<20%) Medium risk (20-80%) High risk (>80%) 
Acute lymphoblastic leukaemia 
Wilms’ tumour 
Soft tissue sarcoma: stage I 
Germ cell tumours: with 
gonadal preservation and no 
radiotherapy 
Retinoblastoma 
Brain tumour: surgery only or 
cranial irradiation <24 Gy 




Soft tissue sarcoma: stage II-III 
Neuroblastoma 
Non-Hodgkin lymphoma 
Hodgkin disease: alternating 
(‘hybrid’) therapy 
Brain tumour: craniospinal 
radiotherapy or cranial 
irradiation >24 Gy 
Total body irradiation 
Chemotherapy conditioning for 
bone marrow transplant 
Localised radiotherapy: pelvic/ 
testicular 
Hodgkin disease: alkylating 
agent-based therapy 
Soft tissue sarcoma: metastatic/ 
stage IV 
Ewing’s sarcoma: metastatic/ 
stage IV 
Table 1: Best estimate guidance for estimating risk of subfertility from various treatment modalities 






Figure 1: Schematic representation of the hypothalamopituitary-testicular axis and potential sites of 
disruption secondary to various cancer treatment modalities as indicated by the red arrows. Thin blue 
arrows indicate physiological negative feedback mechanisms. LH, luteinising hormone; FSH, follicular 
stimulating hormone; Gy, gray. 
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35-45 Gy (cranial) 
Transient impairment of spermatogenesis 
Risk of permanent impairment of spermatogenesis 
Leydig cell dysfunction 
Hypogonadotrophic hypogonadism 
Table 2: Effects of increasing doses of irradiation on hypothalamopituitary-testicular dysfunction. 




Key points in fertility counselling of adolescent boys with cancer 
Pre-treatment: 
Counsel within adolescent-tailored facilities (ideally) 
Counsel before commencement of treatment 
Allow sufficient opportunity to bank samples before treatment 
Clinical assessment – pubertal stage, testicular volume, best estimate of subfertility risk 
Biochemical assessment – LH, FSH, testosterone, inhibin B 
Gillick competence & informed consent including virology (HIV, hepatitis B & C) 
 
Post-treatment: 
Streamlined late effects follow-up (may have other endocrine toxicities) 
Encourage post-treatment semen analysis (do not bank before 3 months) 
Contraceptive advice 
Testicular self-examination 
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